Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Annexon Biosciences ( (ANNX) ) has shared an announcement.
On February 12, 2026, Annexon, Inc. announced that Chairman of the Board Thomas G. Wiggans will retire from the board and not stand for reelection at the company’s 2026 annual meeting of stockholders, at which time his current term as director will end. He will continue to serve as chairman and as a member of the Compensation and Nominating and Corporate Governance Committees until the conclusion of that meeting.
The company highlighted Wiggans’ eight years of service and his positive contributions to Annexon’s development, while stating that his decision was not due to any disagreement over operations, policies, practices, strategy, management or the board. The planned transition signals an orderly board refresh process rather than a response to internal conflict, aiming to maintain governance continuity and stability for stakeholders.
The most recent analyst rating on (ANNX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Annexon Biosciences stock, see the ANNX Stock Forecast page.
Spark’s Take on ANNX Stock
According to Spark, TipRanks’ AI Analyst, ANNX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn), despite a low-debt capital structure. Technicals are strong with an established uptrend, but overbought readings increase near-term pullback risk. Corporate updates and financing improve runway and reinforce late-stage pipeline optionality, while valuation remains unattractive on earnings-based metrics due to ongoing losses.
To see Spark’s full report on ANNX stock, click here.
More about Annexon Biosciences
Annexon, Inc. is a biopharmaceutical company focused on developing therapies targeting the complement pathway of the immune system. The company aims to treat serious autoimmune, neurodegenerative and ophthalmic disorders, positioning itself within the innovative biotechnology sector that addresses high unmet medical needs.
Average Trading Volume: 2,883,115
Technical Sentiment Signal: Buy
Current Market Cap: $707.7M
For an in-depth examination of ANNX stock, go to TipRanks’ Overview page.